Beam Therapeutics
BEAM
231 hedge funds and large institutions have $2.02B invested in Beam Therapeutics in 2024 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 82 increasing their positions, 65 reducing their positions, and 23 closing their positions.
81% more call options, than puts
Call options by funds: $6.96M | Put options by funds: $3.86M
57% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 23
26% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 65
5% more funds holding
Funds holding: 221 → 231 (+10)
2.53% more ownership
Funds ownership: 95.83% → 98.36% (+2.5%)
4% more capital invested
Capital invested by funds: $1.94B → $2.02B (+$85M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$41.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$14.4M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$13.7M |
| 4 |
CC
Casdin Capital
New York
|
+$12.1M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$22.8M |
| 2 |
State Street
Boston,
Massachusetts
|
-$21.7M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$12.3M |
| 4 |
Morgan Stanley
New York
|
-$10.5M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$10.3M |
BEAM Hedge Fund Activity: Q4 2024 in Review
231 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q4 2024, worth a combined $2.02B — up 4.4% from $1.94B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new BEAM positions and 23 closed out — a net gain of 13 holders — while 82 added to existing stakes and 65 trimmed.
The largest buyer was UBS Group, adding an estimated $41.6M. The largest seller was Fidelity Investments, cutting an estimated $22.8M.
- 231 institutional investors held Beam Therapeutics (BEAM) as of Q4 2024, up from 221 in Q3 2024.
- Funds reported $2.02B of Beam Therapeutics stock for Q4 2024, up 4.4% quarter-over-quarter.
- 36 funds opened new Beam Therapeutics positions in Q4 2024 and 23 closed out, a net change of +13 holders.
- The largest Beam Therapeutics buyer in Q4 2024 was UBS Group, an estimated $41.6M added.
- The largest Beam Therapeutics seller in Q4 2024 was Fidelity Investments, an estimated $22.8M sold.
Based on aggregated 13F filings for Q4 2024.